Analysts fell to the sidelines weighing in on Apollo Endosurgery (APEN – Research Report) and Bioventus (BVS – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
Apollo Endosurgery (APEN)
Apollo Endosurgery received a Hold rating and a $10.00 price target from Lake Street analyst Frank Takkinen today. The company’s shares closed last Wednesday at $10.12, close to its 52-week high of $10.30.
According to TipRanks.com, Takkinen is ranked 0 out of 5 stars with an average return of
Apollo Endosurgery has an analyst consensus of Moderate Buy, with a price target consensus of $12.00.
See the top stocks recommended by analysts >>
Bioventus (BVS)
Goldman Sachs analyst Amit Hazan maintained a Hold rating on Bioventus today and set a price target of $2.50. The company’s shares closed last Wednesday at $1.87, close to its 52-week low of $1.65.
According to TipRanks.com, Hazan is a 4-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Bioventus with a $4.50 average price target, representing a 141.9% upside. In a report issued on November 22, Craig-Hallum also downgraded the stock to Hold.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on APEN:
